CBAY - CymaBay Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.19
+0.24 (+2.01%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close11.95
Open12.03
Bid0.00 x 800
Ask0.00 x 900
Day's Range11.91 - 12.33
52 Week Range5.91 - 15.59
Volume408,524
Avg. Volume865,984
Market Cap719.854M
Beta2.45
PE Ratio (TTM)N/A
EPS (TTM)-0.95
Earnings DateAug 8, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.33
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    CymaBay Therapeutics to Participate in Upcoming Investor Conferences in August and September

    NEWARK, Calif., Aug. 14, 2018-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced ...

  • GlobeNewswire7 days ago

    CymaBay Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    Conference call and webcast today at 4:30p.m. ET. NEWARK, Calif., Aug. 09, 2018-- CymaBay Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for liver and other ...

  • GlobeNewswire15 days ago

    CymaBay to Report Second Quarter 2018 Financial Results on Thursday, August 9

    NEWARK, Calif., Aug. 02, 2018-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced ...

  • New Strong Sell Stocks for August 2nd
    Zacks15 days ago

    New Strong Sell Stocks for August 2nd

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • GlobeNewswire16 days ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Five Prime Therapeutics, Akorn, The Blackstone Group, Avaya, Tractor Supply, and CymaBay Therapeutics — New Research Emphasizes Economic Growth

    NEW YORK, Aug. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Five ...

  • GlobeNewswire2 months ago

    CymaBay Therapeutics Added to the Russell 3000® and Russell 2000® Indexes

    CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that is being added to the Russell 3000® and the Russell 2000® Indexes at the conclusion of the Russell US Indexes annual reconstitution, effective after the U.S. market opens on June 25. Annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of May 11, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.

  • GlobeNewswire2 months ago

    CymaBay Therapeutics to Host Analyst and Investor Day on June 26, 2018

    CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, will host an analyst and investor day on June 26, 2018 from 12:00pm to 2:00pm Eastern Time in New York City. Members of CymaBay’s senior management team will provide an update on the company's clinical development of seladelpar in patients with primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). The meeting will also feature presentations by prominent liver experts Dr. Christopher Bowlus, UC Davis Health, Dr. Stephen Harrison, Pinnacle Clinical Research, and Dr. Gideon Hirschfield, University of Birmingham, UK, who will discuss their perspectives on current and novel approaches to treating PBC and NASH.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of CBAY earnings conference call or presentation 8-May-18 8:30pm GMT

    Q1 2018 CymaBay Therapeutics Inc Earnings Call

  • ACCESSWIRE3 months ago

    Wired News – CymaBay Therapeutics Starts Phase-2b Clinical Trials of Seladelpar for Treatment of Patients with Non-Alcoholic Steatohepatitis

    LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on CymaBay Therapeutics, Inc. (NASDAQ: CBAY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CBAY as the Company's latest news hit the wire. On May 08, 2018, the Company announced the initiation of Phase-2b proof of concept clinical trials of seladelpar for the treatment of patients with non-alcoholic steatohepatitis (NASH). The Company started the Phase-2b study with the screening of patients for the clinical trials.

  • Analysts’ Ratings for Achaogen and Peers in April 2018
    Market Realist4 months ago

    Analysts’ Ratings for Achaogen and Peers in April 2018

    Achaogen (AKAO), a late-stage biopharmaceutical company, develops and commercializes antibacterial treatments for MDR (multidrug-resistant) gram-negative infections. Its lead product candidate, plazomicin, targets serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, which was identified as a “nightmare bacteria” by the Centers for Disease Control and Prevention in 2013. Of the 12 analysts covering Achaogen in April 2018, five have recommended a “strong buy,” six have recommended a “buy,” and one has recommended a “sell.” The mean rating for the stock is 1.8, and its target price is $21.56.

  • How Has CymaBay Therapeutics Performed Financially?
    Market Realist4 months ago

    How Has CymaBay Therapeutics Performed Financially?

    CymaBay Therapeutics’ (CBAY) MBX-2982 is under evaluation as a novel therapeutic agent. The company has yet to disclose its target indication. The drug was synthesized as a GPR119 agonist and is shown to increase glucose-dependent insulin secretion in animal models and in vitro. Non-clinical studies have shown MBX-2982 to have desirable effects on blood glucose levels.

  • Exploring CymaBay’s Other Promising Product Candidates
    Market Realist4 months ago

    Exploring CymaBay’s Other Promising Product Candidates

    CymaBay Therapeutics’ (CBAY) second product candidate, arhalofenate, is being developed for the treatment of gout. The drug has been studied in five phase two clinical trials in patients suffering from gout and has consistently demonstrated reduction of gout flares and serum uric acid (or sUA). Gout flares are recurring and painful episodes of joint inflammation.

  • Key Updates on CymaBay’s Lead Product Candidate
    Market Realist4 months ago

    Key Updates on CymaBay’s Lead Product Candidate

    CymaBay Therapeutics (CBAY) is currently developing seladelpar for treating primary biliary cholangitis (or PBC), which is an autoimmune disease that causes progressive destruction of the bile ducts in the liver. The company also plans to develop seladelpar for treating non-alcoholic steatohepatitis (or NASH). NASH is a serious chronic liver disease caused by excessive fat accumulation in the liver, which results in inflammation and cellular injury that can progress to fibrosis and cirrhosis and potentially liver failure.

  • What Analysts Recommend for CymaBay Therapeutics
    Market Realist4 months ago

    What Analysts Recommend for CymaBay Therapeutics

    CymaBay Therapeutics (CBAY) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for patients with liver disease and other chronic diseases. Of the eight analysts covering CymaBay Therapeutics in April 2018, two analysts have given the stock a “strong buy” rating, and six analysts have given it a “buy” rating. Of the total 22 analysts covering Pfizer (PFE) in April 2018, two analysts have given the stock a “strong buy” rating, and nine analysts have given it a “buy” rating.

  • ACCESSWIRE4 months ago

    Wired News – CymaBay to Present Positive Results from Phase-2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at the EASL Liver Meeting 2018

    Stock Monitor: Can-Fite BioPharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free research report on CymaBay Therapeutics, Inc. (NASDAQ: ...

  • CymaBay Therapeutics (CBAY) in Focus: Stock Moves 11.4% Higher
    Zacks4 months ago

    CymaBay Therapeutics (CBAY) in Focus: Stock Moves 11.4% Higher

    CymaBay Therapeutics (CBAY) was a big mover last session, as the company saw its shares rise more than 11% on the day.

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: Keryx Biopharmaceuticals and CymaBay Therapeutics

    NEW YORK, NY / ACCESSWIRE / April 12, 2018 / Biotech stocks Keryx and CymaBay were both flying higher in Wednesday trading on positive news. Keryx announced that it had received the 2018 Corporate Innovator ...

  • Could This Tiny Biotech Rout Intercept In Liver Disease Drugs?
    Investor's Business Daily4 months ago

    Could This Tiny Biotech Rout Intercept In Liver Disease Drugs?

    CymaBay launched to a month-high Wednesday after unveiling strong data for a liver disease treatment — to the detriment of Intercept which has struggled with its rival drug.

  • TheStreet.com4 months ago

    5 Small-Cap Stocks With Explosive Upside Potential

    These five stocks may be small but top analysts see big potential ahead. Here are the names you must know about.